Arca
Skip to content
Tools
Tools

Postmarketing Studies

After approving a drug, FDA can require more studies: on safety, in children, or to confirm a benefit for drugs approved early. Companies also commit to some voluntarily. This is every one FDA tracks, with whether it is on time.

2,576 studies FDA required, or companies committed to, after approving a drug or biologic: 2,138 still open, 658 of them marked delayed by FDA.

  • Open: 2,138
  • Delayed: 658
  • Past their final report date: 377
  • Open confirmatory trials: 112, for accelerated approvals

Where open studies stand

FDA's status for each open study. Click one to filter the table.

What FDA asked for

Open studies by type.

Most delayed studies

Companies with the most studies FDA marks delayed.

Every study

Delayed first, then by due date; each product opens its application

2,576 studies

What FDA asked for
Kinlytic (urokinase)BLA 21846 ยท Microbix Biosystems Inc.CommitmentPMC 187-7: To conduct a study to assess the immunogenicity of Urokinase after primary dosing. Abbott will agree on a study design with CBER prior to initiating the study.DelayedDec 31, 2004
Zanaflex (tizanidine hydrochloride)NDA 21447 ยท Legacy Pharma Inc SezcPediatric study (PREA)PMR 1739-1: Deferred pediatric study of tizanidine for acute treatment of spasticity in pediatric patients ages 0 to 16.DelayedDec 31, 2005
Zegerid (omeprazole and sodium bicarbonate)NDA 21636 ยท Salix Pharmaceuticals IncPediatric study (PREA)PMR 810-2: Single and multiple-dose pharmacokinetics (PK), pharmacodynamics (PD) and safety study in pediatric patients aged 12 to 16 years.DelayedJul 15, 2007
Zegerid (omeprazole and sodium bicarbonate)NDA 21636 ยท Salix Pharmaceuticals IncPediatric study (PREA)PMR 810-1: Single and multiple-dose pharmacokinetics (PK), pharmacodynamics (PD) and safety study in pediatric patients aged 2 to 11 years.DelayedJul 15, 2007
Nexium (esomeprazole magnesium)NDA 21957 ยท AstraZeneca Pharmaceuticals LPPediatric study (PREA)PMR 59-1: Deferred pediatric study under PREA for the treatment of Gastroesophageal Reflux Disease (GERD): Healing of Erosive Esophagitis, Maintenance of Healing of Erosive Esophagitis, Symptomatic Gastroesophagealโ€ฆDelayedJun 30, 2008
Oraqix (lidocaine and prilocaine)NDA 21451 ยท Dentsply PharmaceuticalPediatric study (PREA)PMR 1440-2: We are deferring pediatric studies for ages 6-17 years for this application.DelayedDec 19, 2008
Zegerid (omeprazole and sodium bicarbonate)NDA 21706 ยท Santarus IncPediatric study (PREA)PMR 1584-1: Deferred pediatric study under PREA for the treatment or prevention of upper gastrointestinal bleeding in critically ill pediatric patients ages 2 to 11 years old and 12 to 16 years old.DelayedDec 26, 2008
Zegerid (omeprazole and sodium bicarbonate)NDA 21636 ยท Salix Pharmaceuticals IncPediatric study (PREA)PMR 1584-1: Deferred pediatric study under PREA for the treatment or prevention of upper gastrointestinal bleeding in critically ill pediatric patients ages 2 to 11 years old and 12 to 16 years old.DelayedDec 26, 2008
Cleviprex (clevidipine butyrate)NDA 22156 ยท Chiesi USA IncPediatric study (PREA)PMR 1258-1: Deferred pediatric studies under PREA for the reduction of blood pressure in pediatric patients ages 1 to 16 years old.DelayedAug 1, 2011
Nexiclon XR (clonidine)NDA 22499 ยท Tris Pharma IncCommitmentPMC 1579-2: You will perform a "Thorough QT Study" as described in ICH E14. This study can utilize your extended release formulation or an immediate release formulation. It can utilize a single 0.6 mg dose group and aโ€ฆDelayedDec 3, 2011
Nexiclon XR (clonidine)NDA 22499 ยท Tris Pharma IncPediatric study (PREA)PMR 1579-1: Deferred pediatric study under PREA for the treatment of hypertension in pediatric patients ages 1 to 18.DelayedDec 3, 2011
Apriso (mesalamine)NDA 22301 ยท Salix Pharmaceuticals IncPediatric study (PREA)PMR 1464-1: Deferred pediatric study under PREA for the maintenance of remission of ulcerative colitis in pediatric patients ages 5 to 17 years to evaluate safety, effectiveness, and pharmacokinetics with Aprisoโ€ฆDelayedJun 1, 2013
Phoslyra (calcium acetate)NDA 22581 ยท Fresenius Medical Care Renal Therapies Group LLCCommitmentPMC 1755-2: A multi-phase clinical trial in a hyperphosphatemic pediatric dialysis population, with a placebo-controlled dose-response phase, followed by an open-label titration and maintenance phase, followed by aโ€ฆDelayedMar 31, 2014
Oravig (miconazole)NDA 22404 ยท Galt Pharmaceuticals LLCPediatric study (PREA)PMR 1635-1: Deferred pediatric study under PREA investigating ORAVIG safety, pharmacokinetics, efficacy and compliance with use instructions in patients with oropharyngeal candidiasis ages > 5 to < or = 17 years.DelayedMar 31, 2014
Sprix (ketorolac tromethamine)NDA 22382 ยท Cosette Pharmaceuticals IncPediatric study (PREA)PMR 1551-2: An open label pharmacokinetic and safety study of SPRIX in pediatric patients ages 12 to less than 17 years of ageDelayedMay 31, 2014
Advil (ibuprofen sodium)NDA 201803 ยท Haleon US Holdings LLCPediatric study (PREA)PMR 1905-1: The applicant currently proposes to develop a liquid pediatric formulation and then perform a pharmacokinetic (PK) study in adults comparing the pediatric formulation to an approved pediatric ibuprofenโ€ฆDelayedJun 30, 2014
Adasuve (loxapine)NDA 22549 ยท Nova Pneuma IncSafety study (FDAAA)PMR 1891-4: Conduct a large, non-randomized, open-label, postmarketing observational study to assess the risks of bronchospasm and related respiratory adverse events and serious outcomes (e.g., hospitalization,โ€ฆDelayedDec 1, 2015
Dilaudid and Dilaudid-HP (hydromorphone hydrochloride)NDA 19034 ยท Fresenius Kabi USA LLCPediatric study (PREA)PMR 347-1: Deferred pediatric study under PREA for the management of pain in patients where an opioid analgesic is appropriate in pediatric patients ages 0 to 16 years.DelayedDec 31, 2015
Beleodaq (belinostat)NDA 206256 ยท Acrotech Biopharma IncSafety study (FDAAA)PMR 2178-6: Evaluate the safety and pharmacokinetics of belinostat in patients with wild-type, heterozygous, and homozygous UGT1A1*28 genotypes. The evaluations should be conducted for sufficient duration and in aโ€ฆDelayedMar 31, 2016
Oxaydo (oxycodone hydrochloride)NDA 202080 ยท Zyla Life Sciences US IncSafety study (FDAAA)PMR 1793-1: An epidemiological study to address whether this formulation of Oxycodone HCl results in a decrease in misuse and abuse, and their consequences: overdose, death and addiction.DelayedJun 30, 2016
Zipsor (diclofenac potassium)NDA 22202 ยท Cosette Pharmaceuticals IncPediatric study (PREA)PMR 1053-2: Deferred pediatric study under PREA for the treatment of relief of mild to moderate acute pain in pediatric patients ages 2 to 12 years.DelayedJun 30, 2016
Uceris (budesonide)NDA 203634 ยท Salix Pharmaceuticals IncPediatric study (PREA)PMR 1997-1: An 8-week randomized, double blind, placebo-controlled trial in children 5 to 17 years of age with active, mild to moderate ulcerative colitis. The trial will evaluate pharmacokinetics (PK), efficacy forโ€ฆDelayedSep 30, 2016
Oxtellar XR (oxcarbazepine)NDA 202810 ยท Supernus Pharmaceuticals IncPediatric study (PREA)PMR 1938-4: A clinical trial to examine pharmacokinetics and tolerability in children, ages 1 month to 6 months, using an age appropriate extended release oxcarbazepine formulation.DelayedDec 31, 2016
Oxtellar XR (oxcarbazepine)NDA 202810 ยท Supernus Pharmaceuticals IncPediatric study (PREA)PMR 1938-3: A clinical trial to examine pharmacokinetics and tolerability in children ages 6 months to 4 years using an age appropriate extended release oxcarbazepine formulation.DelayedDec 31, 2016
LaVivBLA 125348 ยท Fibrocell Technologies, Inc.Safety study (FDAAA)Conduct a study, based on a registry design, to assess the risk of skin cancer in the area of azficel-T injections and the risk of immune-mediated hypersensitivity reactions in 2700 patients who receive azficel-T.DelayedDec 31, 2016
GINTUITBLA 125400 ยท Organogenesis, Inc.Pediatric study (PREA)Assess the safety and effectiveness of Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen for topical (non-submerged) application to a surgically created vascular wound bed in the treatment ofโ€ฆDelayedMar 31, 2017
Zorvolex (diclofenac)NDA 204592 ยท Zyla Life Sciences US IncPediatric study (PREA)PMR 2091-1: An open-label pharmacokinetic and safety study or studies of an ageappropriate formulation of Zorvolex in pediatric patients 6 years to less than 17 years of age with acute pain.DelayedMay 3, 2017
Myobloc (RimabotulinumtoxinB)BLA 103846 ยท Solstice NeuroSciences, LLCCommitmentPMC 2324-10: Randomized,-double-blind, adequately controlled, multiple fixed doses, parallel group clinical trials of Myobloc (botulinum toxin Type B) in the following populations: botulinum toxin-naive children ageโ€ฆDelayedMay 31, 2017
Aralast; Aralast NPBLA 125039 ยท Takeda Pharmaceuticals U.S.A., Inc.CommitmentConduct and report the results of a pilot trial to determine the effect of regular administration of the product on one or more clinically meaningful endpoint(s). Examples of acceptable endpoints include pulmonaryโ€ฆDelayedJul 31, 2017
Suprep Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate)NDA 22372 ยท Azurity Pharmaceuticals IncPediatric study (PREA)PMR 1580-4: Conduct a randomized, single-blind, multicenter dose ranging study comparing the safety and efficacy of SUPREP to NuLytely in children (3 years to 11 years).DelayedNov 30, 2017
Zorvolex (diclofenac)NDA 204592 ยท Zyla Life Sciences US IncPediatric study (PREA)PMR 2091-2: An open-label pharmacokinetic and safety study or studies of an ageappropriate formulation of Zorvolex in pediatric patients 2 years to less than 6 years of age with acute pain.DelayedJan 6, 2018
Uceris (budesonide)NDA 205613 ยท Salix Pharmaceuticals IncCommitmentPMC 2800-1: A 6-week randomized, double blind, placebo-controlled trial in children 5 to 17 years of age with active, mild to moderate distal ulcerative colitis (extending up to 40 cm from the anal verge). The trialโ€ฆDelayedApr 30, 2018
Treximet (naproxen sodium and sumatriptan)NDA 21926 ยท Azurity Pharmaceuticals IncPediatric study (PREA)PMR 2910-1: Conduct a juvenile rat toxicology study to identify the unexpected serious risk of adverse effects of sumatriptan/naproxen on postnatal growth and development. The study should utilize animals of an ageโ€ฆDelayedMay 31, 2018
Treximet (naproxen sodium and sumatriptan)NDA 21926 ยท Azurity Pharmaceuticals IncPediatric study (PREA)PMR 2910-1: Conduct a juvenile rat toxicology study to identify the unexpected serious risk of adverse effects of sumatriptan/naproxen on postnatal growth and development. The study should utilize animals of an ageโ€ฆDelayedMay 31, 2018
TalcNDA 21388 ยท Sciarra Laboratories IncSafety study (FDAAA)PMR 3332-1: Perform a risk assessment study on the lead content of sterile talc powder and indicate any necessary controls on elemental impurities as per ICH Q3D Elemental Impurities: Guidance for Industry.DelayedMay 31, 2018
Sclerosol Intrapleural Aerosol (talc)NDA 20587 ยท Sciarra Laboratories IncSafety study (FDAAA)PMR 3325-1: Perform a risk assessment study on the lead content of sterile talc powder and indicate any necessary controls on elemental impurities as per ICH Q3D Elemental Impurities: Guidance for Industry.DelayedMay 31, 2018
Diclegis (doxylamine succinate and pyridoxine hydrochloride)NDA 21876 ยท Duchesnay IncPediatric study (PREA)PMR 2033-1: An adequately powered safety and efficacy study in pregnant adolescent girls, 12 to 17 years of age, with nausea and vomiting of pregnancy who are appropriate candidates for pharmacologic therapy.DelayedJul 31, 2018
Xifaxan (rifaximin)NDA 21361 ยท Salix Pharmaceuticals IncPediatric study (PREA)PMR 858-1: Deferred pediatric studies under PREA for the treatment of traveler's diarrhea in pediatric patients ages 3 years to 12 years. Final Report Submission: May 1, 2009.DelayedJul 31, 2018
Probuphine (buprenorphine)NDA 204442 ยท Reacx Pharmaceuticals IncSafety study (FDAAA)PMR 3078-4: Clinical trial to evaluate the safety, feasibility, and pharmacokinetics of PROBUPHINE (buprenorphine hydrochloride) implantation at alternate body sites. The trial should also evaluate the safety of otherโ€ฆDelayedAug 31, 2018
GlassiaBLA 125325 ยท Takeda Pharmaceuticals U.S.A., Inc.CommitmentKamada Ltd. commits to conduct and report the results of a Human Factors study, to evaluate the types of problems that patients/caregivers may encounter in self-infusing. This information will be used to revise, asโ€ฆDelayedAug 31, 2018
Hemlibra (emicizumab-kxwh)BLA 761083 ยท Genentech, Inc.CommitmentPMC 3299-1: Conduct an assessment of binding anti-product antibody (APA) responses with a validated assay capable of sensitively detecting APA responses in the presence of emicizumab levels that are expected to beโ€ฆDelayedJan 31, 2019
Aplenzin (bupropion hydrobromide)NDA 22108 ยท Bausch Health US LLCPediatric study (PREA)PMR 133-1: Deferred pediatric study under PREA for the treatment of Major Depressive Disorder in pediatric patients ages 7 to 17.DelayedFeb 28, 2019
Xifaxan (rifaximin)NDA 21361 ยท Salix Pharmaceuticals IncPediatric study (PREA)PMR 2900-1: Conduct a pharmacokinetic, pharmacodynamics, tolerability and dose ranging study in subjects 6 years through 17 years, to assess safety and to determine the doses to be used in the efficacy study.โ€ฆDelayedMar 31, 2019
Myobloc (RimabotulinumtoxinB)BLA 103846 ยท Solstice NeuroSciences, LLCSafety study (FDAAA)PMR 2324-9: Submit safety data assessing distant spread of toxin effects after multiple administrations off Myobloc (botulinum toxin Type B), during a minimum period of 12 months, collected in at least 100 pediatricโ€ฆDelayedMar 31, 2019
Suprep Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate)NDA 22372 ยท Azurity Pharmaceuticals IncPediatric study (PREA)PMR 1580-9: Conduct a randomized, single-blind, multicenter dose ranging study comparing the safety and efficacy of SUPREP to NuLytely in children (6 months to 2 years).DelayedMay 31, 2019
Siliq (brodalumab)BLA 761032 ยท Bausch Health Ireland, LimitedPediatric study (PREA)PMR 3164-1: Open-label study to determine PK of a single dose of brodalumab in 16 children (6 to < 18 years old) with severe plaque psoriasis.DelayedJun 30, 2019
Probuphine (buprenorphine)NDA 204442 ยท Reacx Pharmaceuticals IncSafety study (FDAAA)PMR 3078-3: Clinical trial to evaluate the effect of scarring or inflammation related to a prior implant on the safety of re-implantation/reinsertion, the potential for migration of implants, and the bioavailability ofโ€ฆDelayedAug 31, 2019
Xtampza ER (oxycodone)NDA 208090 ยท Collegium Pharmaceutical IncSafety study (FDAAA)PMR 3033-11: Conduct a clinical trial to estimate the serious risk for the development of hyperalgesia following the long-term use of high-dose ER/LA opioid analgesics for at least one year to treat chronic pain.โ€ฆDelayedAug 31, 2019
Belbuca (buprenorphine hydrochloride)NDA 207932 ยท Biodelivery Sciences International IncSafety study (FDAAA)PMR 3033-11: Conduct a clinical trial to estimate the serious risk for the development of hyperalgesia following the long-term use of high-dose ER/LA opioid analgesics for at least one year to treat chronic pain.โ€ฆDelayedAug 31, 2019
Hysingla ER (hydrocodone bitartrate)NDA 206627 ยท Knoa Pharma LLCSafety study (FDAAA)PMR 3033-11: Conduct a clinical trial to estimate the serious risk for the development of hyperalgesia following the long-term use of high-dose ER/LA opioid analgesics for at least one year to treat chronic pain.โ€ฆDelayedAug 31, 2019

Requirements (PMRs) are studies FDA can compel: safety studies under FDAAA, pediatric studies under PREA, and confirmatory trials for accelerated approvals. Commitments (PMCs) are studies a company agreed to. FDA's file lists open studies and those closed in roughly the last year, with FDA's own status; โ€œpast dueโ€ means the original final report date has passed and FDA has not recorded the report as submitted. Refreshed weekly, last Nov 16, 2026. FDA, Postmarketing Requirements and Commitments database file

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.